Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02996721 · ClinicalTrials.gov registry record · Phase 4
A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients
A Phase 4 study of Myocardial Infarction and Death, sponsored by Intermountain Health Care.
- Completed
- Registry status
- Phase 4
- Development phase
- 634
- Enrollment target
- 1
- Study location
NCT02996721: Completed Phase 4 study of Myocardial Infarction and Death, sponsored by Intermountain Health Care.
NCT02996721 is a Phase 4 study of Myocardial Infarction and Death that has completed, run by Intermountain Health Care. The registered enrollment target is 634 participants, below the 4,672-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02996721, a Phase 4 study of Myocardial Infarction and Death, has completed, sponsored by Intermountain Health Care.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 634 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates whether achieving 25-hydroxyvitamin D (25\[OH\] Vit D) levels (\>40 ng/mL) among myocardial infarction patients will result in a reduction of cardiovascular-related adverse events. Half of the patients will be randomized to receive standard of care and half will receive clinical management of 25\[OH\] Vit D levels.
Conditions Studied
Interventions
- BIOLOGICAL Vitamin D3
Study Locations (1)
Utah
- Intermountain Medical Center - Murray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 634 participants |
| Start Date | 2017-04-03 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 4 |
What the finished NCT02996721 record still lists
NCT02996721 is an interventional study that assigns participants to a tested intervention. The registered 634 participants enrollment target is mid-sized for trials with a published cap, below the 4,672-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (86% lower).
The record links to 4 conditions, with Myocardial Infarction appearing as the primary indexed condition, and to 1 intervention - of which Vitamin D3 is the first listed.
NCT02996721 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT02996721 about?
NCT02996721 is a clinical study titled "A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients". This study evaluates whether achieving 25-hydroxyvitamin D (25\[OH\] Vit D) levels (\>40 ng/mL) among myocardial infarction patients will result in a reduction of cardiovascular-related adverse events. Half of the patients will be randomized to receive standard of care and half will receive clinical...
What is the current status of trial NCT02996721?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 634 participants. The study started on 2017-04-03. Estimated completion is 2025-09-04.
What conditions does trial NCT02996721 study?
This clinical trial studies the following conditions: Myocardial Infarction, Death, Cerebral Vascular Accident, Heart Failure Hospitalization.
What interventions are being tested in trial NCT02996721?
The interventions under investigation include: Vitamin D3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02996721?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02996721 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocardial Infarction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02996721's enrollment target sits among peer trials
634 23rd of 64 higher than 42 of 64 other Myocardial Infarction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myocardial Infarction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
ACTIVE NOT RECRUITING · Phase 4
-
Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization
COMPLETED · Phase 4
-
Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease
COMPLETED · Phase 4
-
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
COMPLETED · Phase 4
-
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
RECRUITING
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573027 · 634 participants · NA
Heart Disease of the Small Arteries in Women and Men
- NCT04108156 · 634 participants · Phase 3
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
- NCT07237295 · 634 participants · NA
CommunityRx-Kidney Health
- NCT03478826 · 635 participants
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI